Table 7. . Immune-related adverse events reported in our cohort.
| Type of iRAE | Grade 1–2 | Grade 3–4 | Management of the AE | ||
|---|---|---|---|---|---|
| Temporary interruption | Systemic steroids | Permanent discontinuation | |||
| Skin AEs | 16 (22.2%) | 0 (0%) | 3 (4.2%) | 6 (8.3%) | 1 (1.4%) |
| Diarrhea | 8 (11.1%) | 1 (1.4%) | 4 (5.6%) | 4 (5.6%) | 0 (0%) |
| Hypothyroidism | 8 (11.1%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Hyperglycemia | 2 (2.8%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Liver enzyme elevation | 6 (8.3%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Pneumonia | 1 (1.4%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Asthenia | 2 (2.8%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Arthralgia | 2 (2.8%) | 0 (0%) | 0 (0%) | 1 (1.4%) | 0 (0%) |
| Renal AEs | 1 (1.4%) | 1 (1.4%) | 2 (2.8%) | 2 (2.8%) | 1 (1.4%) |
| Total patients | 28 (38.9%) | 2 (2.8%) | 9 (12.5%) | 12 (16.7%) | 2 (2.8%) |
AE: Adverse event.